Entrada Therapeutics, Inc. Common Stock (TRDA) Stock Price
TRDAStock
$4.37−29.29%52W
Market Cap$170.15M
P/E7.40x
PEG Ratio—
Div yield—
Beta-0.20
TRDA Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-78.76%
Price vs S&P 500 (4W)-32.86%
VGM Score31.52
P/E Ratio (Annual)7.40x
TRDA Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$1.04 | -$1.01 | +3.15%(+$0.03) | |
| Q1 2026 | -$1.02 | -$0.95 | +6.86%(+$0.07) | |
| Q4 2025 | -$1.16 | -$0.94 | +18.73%(+$0.22) | |
| Q3 2025 | -$0.96 | -$1.06 | -9.84%(-$0.10) | |
| Q2 2025 | -$0.86 | -$1.04 | -20.46%(-$0.18) |
TRDA Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.21
4.21
4.21
4.21
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
TRDAEntrada Therapeutics, Inc. Common Stock | C | F | D | 36.3x | -94.1% | — | — | $4.37 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About Entrada Therapeutics, Inc. Common Stock
Entrada Therapeutics is a clinical-stage biopharmaceutical company developing medicines to treat neuromuscular and ocular diseases using its proprietary Endosomal Escape Vehicle (EEV) platform, which enables efficient delivery of therapeutic molecules into cells. The company's pipeline focuses on oligonucleotide therapies for Duchenne muscular dystrophy through multiple exon-skipping approaches, and includes a partnered program for myotonic dystrophy type 1. By targeting previously inaccessible intracellular sites, Entrada aims to improve therapeutic efficacy for serious genetic diseases.